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Background: Treatment of chronic venous insufficiency (CVI) has largely focused on reflux. Minimally-invasive techniques to
address superficial and perforator reflux have evolved, but correction of deep reflux continues to be challenging. The advent of
intravascular ultrasound (IVUS) scan and minimally invasive venous stent technology have renewed interest in the obstructive
component in CVI pathophysiology. The aim of this study is to assess stent-related and clinical outcomes following treatment
by iliac venous stenting alone in limbs with a combination of iliac vein obstruction and deep venous reflux.
Methods: A total of 528 limbs in 504 patients, ranging in age from 15 to 87, underwent IVUS-guided iliac vein stent
placement to correct obstruction over an 11-year period. The etiology of obstruction was nonthrombotic in 196 (37%),
post-thrombotic in 285 (54%) limbs, and combined in 47 (9%). Clinical severity class of CEAP was C3 in 44%, C4,5 in
27%, and C6 in 25% of stented limbs. Deep venous reflux was present in all limbs, associated with superficial and/or
perforator reflux in 69%. Reflux was severe in 309/528 (59%) limbs (reflux multisegment score>3) and 224/528 (42%)
limbs had axial reflux. Venography and other functional tests had poor diagnostic sensitivity to detect obstruction, which
was ultimately diagnosed by IVUS. The IVUS-guided iliac vein stenting was the only procedure performed and the
associated reflux was left uncorrected.
Results: There was no mortality; morbidity was minor. Cumulative secondary stent patency was 88% at 5 years; no stent
occlusions occurred in nonthrombotic limbs. Cumulative rates of limbs with healed active ulcers, freedom of ulcer
recurrence in legs with healed ulcers (C5), and freedom from leg dermatitis at 5 years were 54%, 88%, and 81%,
respectively. Cumulative rate of substantial improvement of pain and swelling at 5 years was 78% and 55%, respectively.
Quality of life improved significantly. Reflux parameters did not deteriorate after stenting.
Conclusion: Iliac venous stenting alone is sufficient to control symptoms in the majority of patients with combined
outflow obstruction and deep reflux. Partial correction of the pathophysiology in limbs with multisystem or multilevel
disease can provide substantial symptom relief. Percutaneous stent technology in concert with other minimally-invasive
techniques to address superficial and/or perforator reflux offers such partial correction in limbs with advanced CVI and
complex venous pathology. Open correction of obstruction or reflux is now required only infrequently as a “last resort”.
(J Vasc Surg 2010;51:401-9.)Reflux is considered the dominant pathology in chronic
venous insufficiency (CVI). The diagnosis and treatment of
reflux has been the main focus of managing symptomatic
patients with CVI for over a century. It has, however, been
recognized that obstruction alonemay cause symptoms in a
small subset of patients with CVI with post-thrombotic
limbs1 or those with primary disease (May-Thurner syn-
drome).2 Venovenous bypass was the standard in treating
the obstruction in such cases.3 With the use of intravascular
ultrasound scans and other modern imaging technologies,
it is now known that morphologic obstruction of the iliac
veins is ubiquitous4 and can be demonstrated to be present
in the majority of patients with CVI alone or in association
with reflux.5,6 The pathophysiologic significance of this
finding is unclear. Whether or not it is necessary to correct
this iliac vein obstruction in limbs with combined obstruc-
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doi:10.1016/j.jvs.2009.08.032tion/reflux is unknown. The indications for intervention
are not well defined. The advent of percutaneous stent
technology allows for a relatively simple way to correct iliac
vein obstructions, and endovenous stenting has largely
replaced Palma bypass with excellent stent patency and
clinical outcome.7-10 Stenting was initially performed in
patients with CVI with isolated iliac vein obstruction with-
out associated reflux. After having established its safety and
efficacy, stenting was performed as the initial treatment of
patients with combined obstruction and deep venous re-
flux. The intention was to later perform valve reconstruc-
tion with the aim of achieving better symptom relief than
with valve reconstruction alone. Surprisingly, symptom
relief with initial iliac vein stenting was so effective that
additional valve repair was found to be unnecessary in the
majority of patients. The aim of this study is to assess
stent-related and clinical outcomes following treatment by
iliac venous stenting alone in limbs with a combination of
iliac vein obstruction and deep venous reflux. The reflux
remained untreated.
PATIENTS AND METHODS
Iliac vein stenting was performed in a total of 1640
limbs during 1997-2008 (11 years). Of these, 1112 limbs
were excluded from this analysis because deep reflux was
absent or other procedures were carried out concurrent
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analysis: limbs with intravascular ultrasound (IVUS)-
detected iliac vein stenosis with no associated reflux (n 
445); limbs with associated reflux confined to the superfi-
cial system (n  255); limbs with concurrent saphenous
ablation performed along with the stenting (n 366); and
limbs with incomplete information regarding concomitant
reflux (n  46). Current analysis pertains to the remaining
528 stented limbs (32%) with deep venous reflux alone (n 
172) or in combination with untreated superficial or per-
forator reflux (n  356). Iliac vein stenting was the sole
corrective procedure and the reflux component was not
treated.
Indications for iliac vein stenting. Patients with sig-
nificant symptoms of pain (visual analog scale [VAS] 5/
10), marked swelling, stasis skin changes including ulcers,
or combinations of signs and symptoms unresponsive to
conservative measures were considered for iliac vein stent-
ing. As a tertiary referral center, most patients had been
under the care of other physicians before referral for persis-
tent symptoms and treated conservatively, including com-
pression therapy.
Clinical assessment. The study endpoint of legs with
stasis ulceration was complete epithelialization. Primary
nonhealing ulcers were marked as such and censored at 4
months. Any breakdown of an ulcer after healing was
considered a recurrence. The degree of pain was evaluated
perioperatively using a VAS from 0-10, wherein 10 is the
most severe pain.11 Swelling was assessed as grade 0 (ab-
sent); grade 1 (pitting, not obvious); grade 2 (visible ankle
edema); and grade 3 (massive, encompassing the entire
leg). Patients were asked to fill out a health-related quality
of life (QoL) questionnaire (CIVIQ) assessing subjective
leg pain, leg symptoms affecting sleep, work, morale, and
social activities before intervention, and again at each sub-
sequent postoperative visit. The CIVIQ form has a proven
specificity and relevance to chronic venous disease.12 The
last available clinical evaluation was used in postoperative
outcome analysis.
Investigations. Preoperative investigations included
duplex examination, arm/foot venous pressure test,13 am-
bulatory venous pressure (AVP) measurement, percentage
drop, venous filling time (VFT), air plethysmography (ve-
nous filling index [VFI90, mL/second]), and ascending
and transfemoral venography with exercise femoral pres-
sure measurements.14 Tests were performed through the
same venous access, if possible, to minimize venipunctures.
An IVUS examination was the definitive diagnostic test and
was also essential in guiding the stent placement. IVUS
makes it possible to accurately identify the degree of steno-
sis and extent of the lesion by using incorporated software
to use planimetry to measure lumen size and allows calcu-
lation of the cross-cut area stenosis. Intraluminal lesions,
outside compression, and wall thickness can be better
shown by IVUS than venography (Fig 1).15
Technique. When an iliac vein stenosis was confirmed
by IVUS, iliac vein stenting was carried out concurrently.
Details of work-up, technique, and perioperative manage-ment including anticoagulation have been described in
detail before.16-19 The procedure is performed under gen-
eral anesthesia for secure cardiopulmonary control in the
elderly subset and to avoid the pain and discomfort often
associated with iliac vein balloon dilatation. Use of large-
caliber (14-18 mm) stents, stent coverage of all lesions
without skip areas, 3 to 5 cm extension of braided iliac
stents into inferior vena cava, and extension below the
inguinal ligament, as necessary, are essential technical ele-
ments for a successful outcome. Wallstents (Boston Scien-
tific, Nantucket, Mass) were used exclusively. Patients were
discharged after an overnight hospital stay.
Follow-up. Patients were clinically examined at 6
weeks, 3 months, 9 months, and then annually. Stent
patency was established by venography at 3 to 6 months
and yearly thereafter. Duplex ultrasound scanning has been
used in the last 5 years for more frequent stent surveil-
lance.20 When severe in-stent restenosis (50%) was found
during routine surveillance or the clinical response to the
initial stenting was unsatisfactory, IVUS was repeated and
the underlying malfunction was corrected when identi-
fied.21 Reintervention was performed in 20% (17% of limbs
with primary and 23% in limbs with post-thrombotic dis-
ease). Stent malfunction was due to thrombus layering
within the stent, in-stent restenosis or stent compression,
previously missed or new stenosis cephalad, or caudad to
the stent, as described in a previous study.21 Since the last
postoperative response was used in follow-up, the effect of
the reinterventions is incorporated in the cumulative stent
Fig 1. Intravascular ultrasound (IVUS) scan appearance of a
post-thrombotic stenosis. Lumen compromise and wall thickness
are evident. The electronic scale (graticule shown) and planimetry
capabilities of IVUS instrumentation allow accurate assessment of
diffuse and focal stenoses.and clinical outcome.
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medical records that were contemporaneously created dur-
ing clinical evaluation. Continuous and categoric variables
were analyzed by paired nonparametric Wilcoxon-Rank
test and 2 test, respectively. Secondary patency rates and
clinical outcomes were calculated using cumulative analysis
with the Kaplan-Meier method. These curves were pruned
at SEM 10%. Log-rank test was used to compare cumu-
lative curves. A commercially available statistical program
(Graph Pad Prism for Windows, v 3.0; Graphpad Software
Inc, La Jolla, Calif) was used for analysis. P  .05 was
considered significant. The number of subjects for individ-
ual parameters varies as shown because of lack of follow-up,
test not performed due to technical difficulties, or refusal to
have the test, etc. Institutional Review Board (IRB) permis-
sion was not required as retrospective analysis of clinical
record data is presented in anonymous fashion.
RESULTS
IVUS-guided iliac vein stenting was performed in 504
patients (median 55 years; range, 15-87; male/female ratio
was 2:3). Bilateral disease was treated in 24 patients; thus,
528 limbs were included in the study (left/right limb ratio
was 2:1; primary, post-thrombotic and combined etiology in
196 [37%], 285 [54%], and 47 [9%], respectively). CEAP
classification of the treated limbs is shown inTable I.22 All had
advanced CVI symptoms, 96% were C-class of CEAP 3,
and 25% of limbs had active venous ulceration. The indica-
tion for stenting in C2 limbs (4%) was complaint of signif-
icant leg pain (VAS5/10) requiring narcotics for control.
The median duration of symptoms before stenting was 36
months (range, 6-360).
Details of reflux present in stented limbs are shown in
Table II. All patients had deep reflux, which was combined
with superficial reflux in 65% and perforator reflux in 24% of
Table I. CEAP classification of 528 stented limbs
CEAP n (%)
Clinical class:
2 (Varicose veins, pain 5 VAS) 20 (4%)
3 (Venous edema) 232 (44%)
4a (Dermatitis, hyperpigmentation) 74 (14%)
4b (Lipodermatosclerosis, white scar) 33 (6%)
5 (Healed ulcer) 36 (7%)
6 (Active ulcer) 133 (25%)
Etiology:
Primary 196 (37%)
Primary/secondary 47 (9%)
Secondary 285 (54%)
Anatomy:
Deep 164 (31%)
Deep/perforator 21 (4%)
Deep/superficial 238 (45%)
Deep/superficial/perforator 105 (20%)
Pathology:
Obstruction/reflux 528 (100%)
VAS, Visual analog scale.limbs. The rate of different reflux patterns is given in Table I(“A” of CEAP). Global reflux was severe in 309/528 limbs
(59%) with reflux segment score 3, and 224/528 (42%)
limbs had deep axial reflux.
The indications to perform exploration with IVUS
were several (Table III). Venography findings suggesting
iliac vein obstruction included lesions such as webs, “pan
caking”, or translucency at compression points, and obvi-
ous focal or diffuse stenosis (Figs 2 and 3).6 These were
found in 245/386 (63%) of treated limbs, and collaterals
were visualized in 165/382 (43%). The venography was
unrevealing (“normal”) in 141/386 (37%) limbs. Indirect
evidence of obstruction such as obstructive flow pattern on
Doppler scan investigations of the common femoral vein or
at least one abnormal pressure study (femoral vein pressure,
arm/foot pressure difference, and/or reactive hyperemia
pressure augmentation) was present in 403/528 (76%) limbs
prior to IVUS/stenting.Neither venography nor venous test-
ingwas indicative of iliac vein obstruction in 94/497 (19%) of
limbs. IVUS was the only diagnostic test performed prior to
stenting in 31/528 (6%), since other tests were excluded due
Table II. Reflux details in 528 stented limbs
Type of reflux Number of limbs Prevalence (%)
Deep reflux alone 172 33%
 Superficial reflux 343 65%
 Perforator reflux 100 24%
Axial deep reflux 224 42%
Reflux multisegment score* 1: 107 20%
2: 112 21%
3: 140 27%
4: 88 17%
5: 52 10%
6: 23 4%
7: 6 1%
*Reflux in the great saphenous vein (GSV) above the knee, GSV below the
knee, small saphenous vein, perforators, femoral vein, profunda femoris, and
popliteal vein are each given a score of 1. The total reflux score for the limb
is calculated (maximum 7).
Table III. Tests suggestive of iliac venous obstruction
leading to intravascular ultrasound (IVUS) investigation
and stent placement
Number of
tested limbs
%
positive
Transfemoral antegrade venography:
Lesion present 245/386 (63%)
Collaterals visualized 165/382 (43%)
Femoral vein pressures:
3-mm Hg gradient over contralateral
limb 20/133 (15%)
4-mm Hg elevation with exercise 92/175 (53%)
Arm/foot pressure difference 4-mm Hg
at rest 37/228 (16%)
Reactive hyperemia 6-mm Hg at rest 125/224 (56%)
Lack of phasicity on Doppler scan study of
the common femoral vein 250/423 (59%)to clinical or technical considerations.
vein i
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22; significantly worse (P .001) in post-thrombotic limbs
(80% 22) compared to that in primary disease (65% 20;
80%  22). A total of 72% of limbs had the upper stent
placed approximately 3 cm into the inferior vena cava for
technical reasons, as previously described.16 The upper end
of the stent system was placed even higher up to correct
associated caval stenosis in 19% and was limited to the
common iliac vein (CIV) in 9% of limbs. The lower end of
the stent was placed in the CIV, external iliac vein, common
femoral vein, and profunda femoris vein in 9%, 15%, 75%,
and 1% of limbs, respectively. Thus, the majority of patients
had the entire ilio-common femoral vein segment covered
by stent.
Follow-up data were available in 488/528 (92%) limbs
Fig 2. Transfemoral antegrade venogram in a limb with
of the iliac-caval junction can be noted on close inspecti
An obstructive lesion was obvious on intravascular ultr
prior to stenting shows tight focal “waisting” (right).
Fig 3. Diffuse post-thrombotic iliac vein stenoses occu
collateral formation as originally described by Rokitans
inspection in this instance shows an iliac vein that is sub
highlighted by arrows (left). A uniform diameter of thewith a median follow-up of 17 months (range, 1-145). Nomortality occurred (30 days). Early deep venous throm-
bosis (30 days) developed in 11 limbs (2%; 9 ipsilateral
limbs, all involving the stent, and 2 contralateral limbs).
Despite reintervention, the stented vein remained occluded
in 29 post-thrombotic limbs. No occlusion was seen in
limbs stented for primary disease. Cumulative secondary
stent patency rate for all limbs at 5 years was 88% (Fig 4). It
was greater for stented limbs with primary as compared to
post-thrombotic disease (100% and 82%, respectively; P 
.0002).
Cumulative rates of symptom relief following stent
placement are shown in Figs 5 and 6. Significant cumulative
improvement of pain and swelling at 5 years was 78% and
55%, respectively; complete relief was 71% and 36%, respec-
tively. No difference was observed between limbs with
mary obstructive lesion. A translucent slight broadening
ut the venogram appears otherwise unremarkable (left).
d (IVUS) examination. Subsequent balloon dilatation
a constricting perivenous fibrotic sheath that prevents
ch lesions are easily overlooked on venography. Close
ially more narrowed as compared to the femoral vein as
s achieved after iliac vein stent placement (right).a pri
on, b
asounr from
ki. Su
stantnonthrombotic and post-thrombotic obstruction (P 
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and moderate reflux (3 reflux multisegment score; P 
.341) or limbs with axial and nonaxial reflux (P  .905).
Similarly, the cumulative rate of swelling relief was not
significantly different in limbs with nonthrombotic and
post-thrombotic disease (P  .378), limbs with severe and
moderate reflux (P  .326), or limbs with axial reflux as
compared to limbs with segmental reflux (P  .114).
The effect on recurrence of ulcer in limbs with healed
(C5) or active ulcer (C6) or dermatitis (C4a) at the time of
stenting is shown in Fig 7. The cumulative rates of healing
of active ulcer and continued freedom of ulcer in C5-limbs
were 54% and 88%, respectively, at 5 years. The cumulative
rate of healed dermatitis was 81% at 5 years.
Quality of life questionnaires were completed by 395
patients prior to stenting, but collected post-stenting in
only 179 patients because the assessment was introduced
Fig 4. Cumulative secondary stent patency in 395 limbs with
combined obstruction and reflux. Separate cumulative curves are
shown for primary, post-thrombotic, and combined etiologies
(SEM 10%).
Fig 5. Cumulative rate of pain relief after stent placement in 323
patients complaining of pain prior to treatment. Curves represent-
ing limbs with complete relief (no residual pain) and limbs with
substantial improvement are given (SEM 10%). VAS, Visual
analog scale.late in our database. Thus scores from 179 patients wereavailable for comparison pre- as compared to post-stenting.
There was a significant improvement of all five CIVIQ
categories (Table IV). The median pre-stent scores were
the same in the subset of 179 limbs as compared to all 395
patients assessed pre-stenting.
Reflux parameters were assessed in more than 400
limbs prior to stenting, but available after stenting in only
134 to 226 limbs depending on parameter. The median
values of AVP, VFT, and VFI90 in limbs with data available
before and after stenting are shown in Table V. The median
pre-stent values were the same in the subset of limbs as
compared to all limbs assessed pre-stenting.
Open valve reconstruction procedures were carried out
Fig 6. Cumulative rate of swelling relief after stent placement in
367 patients complaining of swelling prior to treatment. Curves
representing limbs with complete relief (no residual swelling) and
substantial improvement are given (SEM 10%).
Fig 7. Cumulative rates of ulcer-free C5 limbs (ie, limbs with
healed ulcers at the time of stenting, n  32), dermatitis-free C4a
limbs (limbs with active dermatitis at the time of stenting, n 57),
and healed ulcers in C6 limbs (limbs with active ulcer at the time of
stenting, n  114; SEM 10%). A grace period of 4 months for
initial healing of limbs with active leg ulcer was allowed at which
time limbs with unhealed ulcers were censored. Similarly, a
5-month grace period was given for dermatitis to heal before the
limbs with on-going dermatitis were censored. This explains the
drop of the curves at 4 and 5 months (33% and 8%, respectively).in 24 limbs (5%) in this series after the iliac vein stent
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pass procedures were performed.
DISCUSSION
This study suggests that iliac venous stenting alone
significantly improved the clinical outcome in patients with
combined iliac venous outflow obstruction and deep ve-
nous reflux even though the deep reflux component was
left uncorrected. Stenting was safely performed with low
morbidity and excellent long-term patency. Improvement
of the pain was durable over the 5-year observation period,
but the control of leg swelling was less effective. Limb
swelling is the most difficult of venous symptoms to cure
and is generally well tolerated if there is no associated pain.
More than half of the patients with ulcers remained healed
after 5 years. Patients treated because of previous leg ulcer,
but healed at the time of stenting, and those with leg
dermatitis had low cumulative recurrence rates at 5 years
(12% and 19%, respectively). The patients’ QoL signifi-
cantly improved. This unexpected impact by stenting alone
in these limbs with advanced chronic venous disease (CVD)
and uncorrected remaining deep reflux suggests that, first,
stenting alone is sufficient to control symptoms in the
majority of patients with deep reflux, and secondly, that
partial correction of the pathophysiology in limbs with
multisystem disease can provide substantial symptom relief.
Valve incompetence, especially deep venous reflux, is
often found in patients resistant to conservative therapy.
The prevailing clinical practice is to address this reflux
component. Ulcer healing and substantial improvement of
Table IV. Comparison of the scoring of quality of life
according to the CIVIQ questionnaire in 179 patients
assessed before and after stenting (median [range];
paired, nonparametric test)
CIVIQ categories Pre-stent Post-stent P value
Pain 4 (1-5) 3 (1-5)  .0001*
Work 4 (1-5) 3 (1-5)  .0001*
Sleep 3 (1-5) 2 (1-5) .0002*
Social 3.3 (1-5) 2.6 (1-5)  .0001*
Morale 2.9 (1-5) 2.6 (1-5) .0029*
Total 68 (20-100) 53 (20-100)  .0001*
*There was a significant improvement in all five categories.
Table V. Comparison of reflux measurements performed
before and after iliac venous stent placement (median
[range]; paired, nonparametric test)
n Pre-stent Post-stent P value
AVP, % drop 136 62 (0-100) 64 (19-100) 0.23
VFT, second 134 16 (1-123) 18 (2-160) 0.96
VFI90, mL/second 226 2.8 (0-16.6) 2.2 (0-14.1) 0.02*
n, Number; AVP, ambulatory venous pressure; VFT, venous filling time;
VFI90, venous filling time.
*Significant.symptoms have been clearly documented to occur whenunderlying deep reflux is corrected.23,24 Several reports
suggest, however, that an obstructive component is also
commonly present in limbs with CVI of both post-thrombotic
and nonthrombotic etiology.5,6,17,25,26 In limbs with pri-
mary nonthrombotic disease, the obstructive lesions occur
at arterial crossover points, not only at the “classic” proxi-
mal location as previously known,27-29 but commonly also
at distal locations at the hypogastric artery crossing and
behind the inguinal ligament.6,30 This explains the fre-
quent stenting of the entire iliofemoral vein segment in this
study (76%). These so-called nonthrombotic iliac vein le-
sions (NIVLs) are found on both sides, in both genders,
and in all age groups. The pathologic significance of the
lesions has been debated for a long time, as varying degrees
of NIVLs are present in two-thirds of the general popula-
tion in silent form.4 It has been suggested that NIVLs play
a silent “permissive” role that precipitates symptoms only
with additional insult such as development of reflux.6 The
favorable clinical outcome of stent correction suggests that
the NIVL lesion contributes to the underlying pathophys-
iology. In post-thrombotic disease, the obstructive lesions
are typically segmental with focal accentuations at compres-
sion points across the iliac vein.28 In multilevel post-thrombotic
obstruction, iliac vein lesions are the key pathology as
infrainguinal obstructions are well tolerated due to ade-
quate collateralization.31-33
The obstructive component is seldom investigated in
clinical practice today since the main tool for diagnosis is an
infrainguinal ultrasound scan. The pelvic outflow is rarely
routinely investigated. It is important to consider obstruc-
tion as a contributing factor in all patients with symptom-
atic CVI, even those of primary etiology where deep reflux
may be obvious and obstruction is not apparent. It is not
known at what degree a venous stenosis becomes critical,
and accurate noninvasive or invasive hemodynamic tests
are, therefore, not available. A positive test supports further
investigations, but a negative cannot exclude the presence
of a significant obstruction. The diagnosis of occlusive or
nonocclusive obstruction is, therefore, based on morpho-
logic studies (50% stenosis is considered significant, and
this degree is arbitrarily chosen based on clinical outcome).
Since ultrasound scanning of the pelvic outflow is sub-
optimal in the detection of obstruction, additional studies,
such as transfemoral venography, magnetic resonance
(MR-) or computed tomography (CT)-venography, may
be performed in patients with severe chronic venous dis-
ease. Contrast venography is poor in detecting pathologi-
cally important iliac vein lesions. Ascending venography
using a dorsal foot vein often does not yield adequate
opacification for proper iliac vein assessment. Transfemoral
venography is required. Routine radiologic interpretation is
often cursory (“iliac veins are patent”), unless obvious webs
or obstruction are present. Some radiologic texts even
indicate that the presence of transpelvic collaterals is a
“normal anatomic variant”. Venographic indications of
iliac vein lesions are often subtle and require a high index of
suspicion for proper identification of obstruction. Even
given the observer bias of the authors, venography was
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with collaterals being present only in 43% of limbs. The
ultimate arbitrator is IVUS and a readiness to use this tool
is required. IVUS has excellent sensitivity (90%) to detect
iliac vein obstruction.5,6,15 Because of the high diagnostic
yield of IVUS in severely symptomatic patients, it should be
used routinely even if venography is negative for obstruc-
tion. Venography preceding IVUS is still valuable as it
detects collateral formation, better visualizes the continu-
ous outflow, and provides a helpful “road map” for the
stenting procedure. When IVUS has detected a significant
obstruction, stent placement is conveniently combined
with the diagnostic procedure with prior consent. The
sensitivity to detect venous obstruction of high-resolution
imaging techniques (MR-venography and CT-venogra-
phy) is unknown, although initial reports are promising.
Symptom relief with partial correction of multisystem
or multilevel venous pathology utilizing a variety of correc-
tive techniques, other than stenting, has been well docu-
mented.34-38 Ulcer healing and substantial improvement of
symptoms have been reported after repair of the deep valves
alone in complex venous pathology.23,24,31,39,40 In this
report, clinical outcome of stenting without correction of
associated deep reflux, which was severe in the majority of
stented limbs, was substantial and durable. Healing of stasis
ulceration after stenting in the presence of deep reflux was
the most surprising finding. Prevailing concept imputes
ulcer formation to reflux, not obstruction. This study sug-
gests that obstruction also plays a role and correction of
either component (partial correction) can afford relief.
With currently available technology, it is far easier to cor-
rect obstruction than deep reflux. The techniques available
for open repair of the deep valves have not been widely
adopted because of their complexity.
Minimally invasive interventions that are safe and effica-
cious have evolved to correct all of the pathologic components
of CVI except deep venous reflux. These new interventions in
combinationwith the lack of tests, which are available to assess
the contribution of each refluxing or obstructive vein segment
to the global hemodynamics, have changed the therapeutic
approach. Since partial correction of the venous pathology
may result in substantial improvement or complete relief of
symptoms, a stepwise correction of pathology may be applied
using initially minimally-invasive techniques. The current re-
port suggests that deep reflux can be initially ignored if it is
combinedwith iliac vein obstruction, which can be relieved by
stent placement. Complex open surgeries to correct obstruc-
tion or reflux are only performed when percutaneous treat-
ment fails and should be required infrequently (in this study,
in only 5% of stented limbs).
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Dr Harry Schanzer (New York, NY). The paper just pre-
sented byDr Raju et al is extremely important because it challenges
all the previous concepts of pathogenesis and treatment of chronic
venous insufficiency. Dr Raju, you have really put upside down all
our previous notions of venous disease. I have carefully followed
your experience over the years. Initially, you reported excellent
results with valvular reconstruction even in the setting of postphle-
bitic syndrome. Later on, you reported improved results with iliac
vein stenting in the postphlebitic syndrome, and now you are
presenting us with the treatment of primary valvular venous insuf-
ficiency by iliac vein stenting. This, if true, is really a revolutionary
change in the conceptual understanding of the pathogenesis of
CVI and its treatment. I have two questions with regards to your
experience.
The first one is: you reported 90% of patients with primary
venous insufficiency having an obstruction of the iliac system as
determined by IVUS. I would like to know how significant is this
obstruction? In a control population with no CVI, how often
would you have these IVUS findings? How significant is this
finding?
The second question is: is there any additional therapy that
you use in these patients that can confuse the results of the
stenting? I specifically refer to elastic compression.
Finally, I think that it is very important to wait for corrobora-
tion of your results. These are very impressive, and if other groups
can reproduce them, this will change significantly the understand-
ing and treatment of venous insufficiency.
Dr Raju. It is clear from modern imaging techniques that
two-thirds of the normal population have obstructive iliac vein
lesions that are silent. IVUS detectable lesions are present in over
90% of patients with chronic venous disease with CEAP clinical
class 3 and higher presentation. Initially, we were worried that we
were treating something that is normally present; but the clinical
outcome, particularly healing of stasis ulceration, suggests that the
obstructive lesion is contributory to the disease process.
No new stockings are issued after stent placement. So, the
reported clinical improvement is due to the stent procedure itself.
Dr Mark Adelman (New York, NY). If you would, briefly
comment on your anticoagulation regimen and how you manage
these stents postimplantation. I imagine most of these patientsnegative, and they are not found to be hypercoagulable, how do
you manage the anticoagulation regimen over the long term?
Dr Raju. If the thrombophilia is absent, they just get aspirin
when they go home. If thrombophilia is present, warfarin is insti-
tuted or continued.
Dr Rabih Chaer (Pittsburgh, Pa). How do you define venous
stenosis on IVUS? What is your definition of a venous stenosis in
general? And what degree of stenosis do you treat with stenting?
Dr Raju. The normal iliac vein measures about 175 to 250 sq
mm. So you can measure the area with IVUS planimetry software
and compute the stenosis. Anything over 50% area stenosis appears
to be clinically significant.
Dr Peter Gloviczki (Rochester, Minn). This is a tremendous
experience, and as Dr Schanzer said, it changes a lot of what we
know about venous disease.
When we measured 23 limbs with venous reflux, we found
that it became worse in 24% after iliocaval stenting. Somy question
is: do you have a subgroup where you see worsening in venous
reflux?
Many patients who need iliac venous stenting also have in-
frainguinal venous reflux or post-thrombotic obstruction. It looks
like you are not recommending elastic compression after venous
stenting even in this group of patients. Could you tell us why not?
Dr Raju. Reflux does not get worse after stenting when the
data are analyzed in aggregate; in fact, there was a small but
significant improvement in VFI90 afterwards. We have not per-
formed intensive subset analysis to examine if this may not be the
case in some limbs.
Most patients that come to us have already gone through
compression programs. In about one-third of patients, compres-
sion is not appropriate because of local condition of the limb or
systemic deterrents to regular use. In others, compression is not
effective or not tolerated. Noncompliance with prescribed stock-
ings is a difficult and often incorrigible problem that we have dealt
with in a separate publication. We allow patients to maintain
current compression regimen (use or nonuse) without modifica-
tion near term after stent placement. Long term, they are allowed
to abandon stockings if it made no difference. Most patients
abandon stockings entirely or limit usage to only ”hard” days if
clinical outcome is successful.
